0.5% Loteprednol etabonate and 0.3% tobramycin combo safe against ocular inflammatory diseases Jacinthlyn Sylvia28 Nov 2022 8:00 PM ISTIn a new study conducted by James Deom and peers it was shown that when utilized to treat different ocular surface inflammatory disorders found in...
Loteprednol etabonate formulated with MPP technology effective in dry eye disease Medha Baranwal10 March 2022 9:00 AM ISTUSA: A review, published in the Dove press journal Clinical Ophthalmology, has described the use of a commercially available formulation of...
